Royalty Pharma (RPRX) said Friday it has agreed to acquire its external manager, RP Management for about $1.1 billion, including 24.5 million in shares that will vest over five to nine years, about $100 million in cash, and the assumption of $380 million of debt.
The transaction is meant to simplify its corporate structure and reduce costs, generating anticipated cash savings of more than $100 million in 2026 and $175 million in 2030, the company said.
The transaction is expected to close in H1, the company said.
The company said it also approved a new $3 billion share repurchase program, including $2 billion in shares it expects to buy back in 2025.
The repurchase program replaces the unused $465 million of the company's $1.0 billion share repurchase program launched in 2023, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.